Navigation Links
Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
Date:7/9/2009

metreleptin 5 mg/placebo; 4) pramlintide 180 mcg/metreleptin 2.5 mg; 5) pramlintide 180 mcg/metreleptin 5 mg; 6) pramlintide 360 mcg/metreleptin 1.25 mg; 7) pramlintide 360 mcg/metreleptin 2.5 mg; or 8) pramlintide 360 mcg/metreleptin 5 mg.

Lifestyle intervention was included throughout study (dietary, exercise and behavioral). Body composition was assessed using DEXA scanning at enrollment and again at study termination. Across all treatment arms, approximately 60% (n=360) of patients were deemed evaluable (subjects who completed at least 24 weeks of treatment on study medication and had no major protocol deviations).

As part of an ongoing extension protocol, study participants may continue on therapy for a total of 52 weeks. Data from this study will be submitted for presentation at a future medical meeting and for publication in a peer-reviewed journal.

About Obesity

Obesity is a chronic disorder that affects millions of people and is linked to increased health risk of several medical conditions including type 2 diabetes, non-alcoholic fatty liver disease, high blood pressure, heart disease, stroke, osteoarthritis, sleep disorders and several types of cancers. According to The Obesity Society, obesity is the second leading cause of preventable death in the United States. The total direct and indirect cost attributed to overweight and obesity health issues exceeds $100 billion in the United States each year. Obesity is also rapidly becoming a major health problem in all industrialized nations and many developing countries.

There are different classes of obesity defined by body mass index, or BMI. Overweight is defined as BMI 25 to 29.9 kg/m2, Obesity Class I is BMI 30 to 34.9 kg/m2, Obesity Class II is BMI 35 to 39.9 kg/m2 and Obesity Class III is BMI 40 kg/m2 or more. Of the over 100 million overweight and obese individuals in the United States, over 80 million have a BMI less t
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Amylin Announces Preliminary Tabulation of Annual Meeting Results
4. Amylin Responds to Eastbourne Letter
5. Amylin Comments on RiskMetrics Report
6. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
7. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
8. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
9. Amylin Issues Statement in Response to Carl Icahn
10. Icahn Asks Amylin to Allow Discussions With Eastbourne
11. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ... solutions, today announced that Lupin Limited, one of ... of Freeslate’s CM Protégé PharmD System ... Lupin, headquartered in Mumbai, India, is focused on ... branded formulations and Active Pharmaceutical Ingredients (APIs) for ...
(Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... developing solutions based on the products of cells ... they have entered into an international license agreement ... containing Histogen’s proprietary multipotent cell conditioned media (CCM). ... to the existing license between Histogen and Suneva ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... are joining together with two institutes from the ... develop more reliable tools for bringing safer, more ... Organovo is collaborating with the National Center for ... Institute (NEI) to develop better and more clinically ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, ... management ( SCM ) and sales and operations planning ... gold sponsor of the Biomanufacturing Summit , which ... January 30 – 31, 2014.  At the conference, join ... Chain at Amgen, as she presents ,Supply Chain: Improving ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Scientific,Corporation (NYSE: BSX ) is scheduled to participate ... being held September 10 and 11,in New York City. ... make a,25-minute presentation followed by a 25-minute question and ... a.m. ET. A live webcast of Mr. LaViolette,s ...
... Artery ... Disease - ... -, FREMONT, Calif., Aug. 28 Vermillion, Inc.,(Nasdaq: VRML ), formerly ... called beta-2,microglobulin may aid in the diagnosis of peripheral artery disease (PAD).,The findings, ...
... (Pink Sheets: BIEL), announced today that Astonix Life,Science, ... provide ActiPatch,Therapy to the healthcare market in Singapore. ... ActiPatch to the market has been warmly,received. ... the Healthcare providers,in Singapore has been strong enough ...
Cached Biology Technology:Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease 2Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease 3BioElectronics Corporation Announces Singapore and Malaysia Sales 2
(Date:4/14/2014)... of subarctic forest moths in Finnish Lapland suggests that ... on animals and plants because much of the harm ... of 80 moth species and found that 90 percent ... study period, from 1978 to 2009. During that time, ... degrees Fahrenheit, and winter precipitation increased as well. , ...
(Date:4/14/2014)... climate over the past three decades have caused small ... national animal. UCLA biologists have found that not only ... has also become shorter and higher pitched. ... integrative biology and physiology and of ecology and evolutionary ... study examined 170 male coqui frogs ( Eleutherodactylus coqui ...
(Date:4/14/2014)... ( http://www.ucr.edu ) David Kisailus, the Winston ... University of California, Riverside,s Bourns College of Engineering, ... Fellows are young scientists selected by the advisory ... National Academy of Sciences and organizers of the ... series. The Kavli Foundation, which is based in ...
Breaking Biology News(10 mins):Moth study suggests hidden climate change impacts 2Moth study suggests hidden climate change impacts 3Climate change a likely culprit in coqui frog's altered calls, say UCLA biologists 2Professor receives young scientist honor 2
... permanently damaged their skin cells, causing them to overproduce ... uneven skin tone over time. But new research indicates ... arthritis ?can actually help stop the formation of new ... findings on glucosamine may impact the way dermatologists treat ...
... warm, sun-drenched, tropical seas; some species are found at ... waters throughout the world's oceans. Some cold-water coral reefs ... a diversity rivaling some better known tropical coral reefs. ... method in which vessels drag large, heavily weighted nets ...
... the rewarding effect of cocaine on mice by genetically ... animal's brain. , While the researchers aren't suggesting that ... brings to light the key protein that controls cocaine's ... medications that achieve the same results and therefore help ...
Cached Biology News:Science finds new fix for UV-damaged skin in arthritis treatment 2Science finds new fix for UV-damaged skin in arthritis treatment 3Ocean acidification threatens cold-water coral ecosystems 2Genetically altered mice no longer like cocaine 2Genetically altered mice no longer like cocaine 3
... GeneBLAzer cell-based assays utilize the ... of the negatively charged fluorescent beta-lactamase ... esters readily enter the cell, where ... converts them into their negatively charged ...
... GeneBLAzer cell-based assays utilize the membrane-permeant ... the negatively charged fluorescent beta-lactamase substrates, ... readily enter the cell, where cleavage ... them into their negatively charged forms, ...
1M stock solution (238mg/ml)...
Request Info...
Biology Products: